Clinical trial
A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Etrolizumab as an Induction And Maintenance Treatment For Patients With Moderately to Severely Active Crohn's Disease
NCT02394028 is registered in ClinicalTrials.gov with Hoffmann-La Roche as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Etrolizumab as an Induction And Maintenance Treatment For Patients With Moderately to Severely Active Crohn's Disease
- Lead sponsor
- Hoffmann-La Roche
- Phase
- Phase 3
- Overall status
- Completed
- Start date
- March 20, 2015
- Completion date
- September 7, 2021
- Enrollment
- 1,035 (actual)
- Sites
- 327
Conditions
As the registry lists them; a condition with its own page is linked.